## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.5% below STRENGTH zone (4.0-10.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (55% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. State Street Corp Cuts Holdings in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251209T132952 | Neutral | Relevance: 99%
-  State Street Corp decreased its stake in Pfizer Inc. by 0.2% during the second quarter, now holding 296,301,310 shares valued at $7.18 billion. Several other institutional investors have also adjusted their positions in Pfizer. The company recently released its quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**2. Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement**
- Source: The Manila Times | 20251209T122153 | Bullish | Relevance: 99%
-  Fosun Pharma's subsidiary, Yao Pharma, has signed an exclusive collaboration and license agreement with Pfizer Inc., granting Pfizer worldwide rights for the development and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002. Yao Pharma will receive an upfront payment of $150 million and is eligible for up to $1.935 billion in milestone payments, plus tiered royalties on sales. This partnership leverages Pfizer's global reach and Yao Pharma's R&D capabilities to accelerate the development of innovative treatments for metabolic diseases such as chronic weight management and type 2 diabetes.

**3. Natixis Has $45.97 Million Stock Holdings in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251208T130837 | Neutral | Relevance: 99%
-  Natixis reduced its stake in Pfizer by 32.4% in the second quarter, now holding 1,896,296 shares valued at approximately $45.97 million. Pfizer analysts maintain a "Hold" rating with an average price target of $28.39, while the company reported strong Q3 EPS and a 6.6% annual dividend yield. Various other institutional investors also adjusted their positions in Pfizer during recent quarters.

**4. Gamco Investors INC. ET AL Trims Stock Holdings in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251208T114541 | Neutral | Relevance: 99%
-  Gamco Investors INC. ET AL reduced its stake in Pfizer Inc. by 15.5% in Q2, selling 122,695 shares and holding 671,241 shares valued at $16.27 million. Despite this, other institutions like Vanguard, Geode Capital, Norges Bank, and Northern Trust increased their positions, ultimately leaving 68.36% of Pfizer owned by institutional investors. Pfizer also reported an EPS beat, set FY2025 guidance, and offers a 6.6% dividend yield.

**5. Pfizer partners with YaoPharma to develop weight management drug**
- Source: Reuters | 20251209T120852 | Somewhat-Bullish | Relevance: 99%
- Pfizer has entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai Fosun Pharmaceutical, to develop and commercialize an experimental weight-management treatment, YP05002. This deal, valued at up to $1.94 billion in milestone payments plus an upfront payment of $150 million, aims to bolster Pfizer's presence in the fast-growing obesity market. The move follows Pfizer's recent acquisition of Metsera and its previous discontinuation of two oral GLP-1 candidates due to safety concerns.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $146.5B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.3 |
| Current P/E | 8.2 |
| YoY Growth | -1.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. Volume at 55% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.47% (CS: 54) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.024x | Above |
| vs SMA200 | 1.050x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.77
- **Stop Loss:** $24.65 (4.3% risk)
- **Target:** $26.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 446
- **Position Value:** $11,493.42
- **Portfolio %:** 11.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*